June 20, 2006 -- Discovery Labs climbed higher after retaining Jeffries to find strategic alternatives; Biomira enlisted bankers to find drugs to in-license or companies to acquire; Praecis said it has not been able to sell Plenaxis; Human Genome sold $165 million worth of ABthrax to the government; the FDA delayed for 90 days its decision on Neurodex from Avanir; Sucampo Pharma and BioVex filed for their IPOs; GE Healthcare offered $390 million for Biacore International; EMD Pharma submitted a new drug application for Cyanokit, a treatment for cyanide poisoning; CuraGen began a Phase II trial of a mesothelioma therapy; ArQule started a Phase II trial of a pancreatic cancer drug; ZymoGenetics completed patient enrollment in a Phase III trial of recombinant human thrombin; and Kos said that Niaspan improved cholesterol control. The Centient Biotech 200™ closed at 3544.82, a loss of 26 points or .72%. More details...
